Safety and tolerability of moxonidine in the treatment of hypertension

Drug Safety

Volumn 19, Issue 3, 1998, Pages 191-203

  Schachter, Michael ^a   Luszick, Joachim ^b   Jäger, Bodo ^b   Verboom, Cees ^b   Söhlke, Eiko ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; DIGOXIN; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; IMIDAZOLINE I2 RECEPTOR; LORAZEPAM; MOXONIDINE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENDER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; SKIN ALLERGY; SOMNOLENCE; THOUGHT DISORDER; VERTIGO; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HUMANS; HYPERTENSION; IMIDAZOLES;

EID: 0031668060     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819030-00003     Document Type: Article

References (43)

1. Whelton PK. Epidimiology of hypertension. Lancet 1994; 344: 101-6
2. Johnston CI. Future management of high blood pressure. J Cardiovasc Pharmacol 1996; 27 (Suppl. 3): S55-60
3. Pickering TG. The effects of environmental and lifestyle factors on blood pressure and the intermediary role of the sympathetic nervous system. J Hum Hypertension 1997; 11 (Suppl. 1): S9-18
4. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
5. Kaplan NM, Weidman P. Introduction: is hypertension a metabolic disease? Am J Heart 1993; 125: 1485-7
6. Julius S, Gudbrandsson T. Early association of sympathetic overactivity, hypertension, insulin resistance, and coronary risk. J Cardiovasc Pharmacol 1992; 20 (Suppl. 8): S40-8
7. Weber MA, Graettinger WF, Cheung DG. Centrally acting sympathetic inhibitors. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1990: 2251-61
8. van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest: mechanisms and haemodynamics. J Hypertension 1997; 15 (Suppl. 1): S3-8
9. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230: 232-6
10. Ernsberger P, Meeley MP, Reis DJ. An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the rostral ventrolateral medulla. Brain Res 1988; 441: 309-18
11. 1 imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172-82
12. Prichard BNC, Graham BR. Effective antihypertensive therapy: blood pressure control with moxonidine. J Cardiovasc Pharmacol 1996; 27 (Suppl. 3): S38-48
13. Webster J, Koch H-F. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27 (Suppl. 3): S49-54
14. Gräve M, Luszick J. Safety summary of clinical trials with moxonidine. Hannover: Solvay Pharmaceuticals GmbH, 1997
15. Wagner W. Periodic drug safety update report moxonidine: 21 Feb 1989-31 Dec 1994. Hannover: Solvay Human Health Division, 1995
16. Söhlke E. Periodic drug safety update report moxonidine: 1 Jan 1995-31 Dec 1995. Hannover: Solvay Human Health Division, 1996
17. Söhlke E. Periodic drug safety update report moxonidine: 1 Jan 1996-31 Dec 1996. Hannover: Solvay Pharmaceuticals, 1997
18. Söhlke E. Periodic drug safety update report moxonidine: 1 Jan 1997-31 Dec 1997. Hannover: Solvay Pharmaceuticals, 1998
19. CIOMS Working Group II. International reporting of periodic drug-safety update summaries. Geneva: CIOMS, 1992
20. ICH Clinical Safety Data Management Guidelines, E2A: definitions and standards for expedited reporting. London: European Medicines Evaluation Agency, 1996
21. ICH Clinical Safety Data Management Giudelines, E2C: periodic safety update reports for marketed drugs. London, European Medicines Evaluation Agency, 1996
22. Tamm M, Sieber C, Schnyder E, et al. Moxonidine-induced cholestatic hepatitis [letter]. Lancet 1997; 350: 1822
23. Ziegler G, Gemeinhardt A. CNS effects of moxonidine, a new central nervous system antihypertensive drug in comparison with clonidine and placebo. Klin Wochenschr 1988; 66 (Suppl. XIII): 41-6
24. Dietrich B, Herrmann WM. Do presynaptic alpha-2 agonists have slighter CNS side effects than postsynaptic agonists? A comparison of moxonidine and clonidine. Eur J Clin Pharmacol 1989; 36 (Suppl.): A45-8
25. Schmidt U, Frerick H, Kraft K, et al. Hypertension: a possible risk in road traffic. J Cardiovasc Pharmacol 1992; 20 (Suppl. 4): S50-6
26. Wesnes K, Sinipson PM, Jansson B, et al. Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Clin Pharmacol 1997; 52: 351-8
27. Theodor RA, Weimann H-J, Weber W, et al. Influence of food on the oral bioavailability of moxonidine. Eur J Drug Metab Pharmacokinet 1992; 17: 61-6
28. Weimann H-J. Pabst G, Weber W, et al. Lack of Pharmacokinetic interaction between moxonidine and hydrochlorothiazide. Eur J Clin Pharmacol 1992; 43: 209-10
29. Pabst G, Weimann H-J, Weber W, et al. Lack of pharmacokinetic interaction between moxonidine and digoxin. Clin Pharmacokinetic 1992; 23: 477-81
30. Müller M, Weimann H-J, Weber W, et al. Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide. Eur J Drug Metab Pharmacokinet 1993; 18: 277-83
31. Kirch W, Hutt HJ, Plänitz V, et al. The influence of renal function in clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245-53
32. Kirch W, Plänitz V. The influence of renal function on clinical pharmacokinetics and antihypertensive effect of moxonidine. Naunyn Scmiedebergs Arch Pharmacol 1987; 335 (Suppl.): R107
33. Feuring M, Cassel W, Stawenow D, et al. Safety of moxonidine in patients with mild-to-moderate hypertension and chronic pulmonary disease [abstract]. European J Clin Pharmacol 1996; 50 Suppl. 6: 533
34. Frei M, Küster L, Gordosch PP, et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1995; 24 Suppl. 1: 25-8
35. Ongyert D, Dotzer F. Wirksamkeit und Verträglichkeit von Moxonidine. Zeit Allgemeinmed 1993; 69: S56-60
36. 1 receptor agonist moxonidine in patients with mild-to-moderate essential hypertension. Eur J Clin Res 1995; 7: 227-40
37. Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20(Suppl. 4): S45-9
38. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20(Suppl. 4): S42-5
39. Epstein M. Calcium antagonist: still appropriate as first line antihypertensive agents. Am J Hypertens 1996; 9: 110-21
40. Furberg CD, Psaty BM. Calcium Antagonist: not appropriate as first line antihypertensive agents. Am J Hypertens 1996; 9: 122-5
41. 1 receptor agonist moxonidine in patients with idiophatic dilated cardiomyophaty and heart failure. Eur J Clin Res 1996; 8: 149-61
42. Rupp H, Maisch B, Brilla CG. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine. Cardiovasc Drugs Ther 1996; 10: 251-62
43. Kaan EC, Brückner R, Frohly P, at al. Effects of agmatine and moxonidine on glucose metabolism: an intergrated approach towards pathophysiological mechanism in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl. 1): 19-27